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Abstract
Since 2003, outbreaks of lymphogranuloma venereum (LGV) have been reported in European countries, North America, and Australia.
Current LGV cases have been caused by Chlamydia trachomatis serovar L2. This sexually transmitted infection is predominantly found
among men who have sex with men, speciﬁcally men who are seropositive for human immunodeﬁciency virus and have clinical signs of
proctitis. The current outbreak has been almost exclusively attributed to a new variant, designated L2b. Although urogenital cases of
LGV have been described in the heterosexual population, we report the ﬁrst case of C. trachomatis L2b proctitis in a woman.
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Abstract
A Klebsiella pneumoniae isolate with decreased susceptibility to carbapenems was isolated in April 2011 in a hospital in Amsterdam (the
Netherlands) and later found to be the source of an important outbreak in a Rotterdam hospital. The strain, belonging to sequence type
(ST) 395, carried the blaOXA-48 gene located onto a c 62-kb conjugative plasmid, together with the extended-spectrum b-lactamase gene
blaCTX-M-15. It was closely related or identical to other OXA-48-positive Klebsiella pneumoniae isolates belonging to the same ST type and
identiﬁed in France and Morocco. This study sheds light on the European dissemination of a single OXA-48 K. pneumoniae clone.
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Abstract
The European Committee on Antimicrobial Susceptibility Testing-Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST)
has determined breakpoints for amphotericin B for Candida spp. This Technical Note is based on the EUCAST amphotericin B rationale
document (available on the EUCAST website: http://www.eucast.org). Species-speciﬁc breakpoints for C. albicans, C. glabrata, C. krusei,
C. parapsilosis and C. tropicalis are S: MIC £1 mg/L, R: MIC > 1 mg/L. There are insufﬁcient data to set breakpoints for other species.
The breakpoints are based upon pharmacokinetic data, epidemiological cut-ff values and clinical experience. Breakpoints will be
reviewed regularly.
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Abstract
Sera from 105 anti-HCV-positive ﬁrst-time blood donors collected in 2004, 2005 and 2008 in different provinces in Laos were investi-
gated by PCR. Forty-ﬁve samples were positive for HCV (42.86%); two belonged to subtype 1b (2/45, 4.4%) and all others to genotype
6 (43/45, 95.6%), including subtypes 6b, 6h, 6k, 6l, 6n and 6q. Three groups of sequences were not clearly attributable to any genotype
6 subtype, two of which may be regarded as candidates for new subtypes of genotype 6. Two samples were mixed infected with differ-
ent subtypes or clusters of genotype 6 viruses.
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